Drug Trial Radar · NCT00003313
Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Nov 21, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
243
Actual
Start
Sep 1998
Primary completion
Jul 2002
Study completion Jun 2010
Sponsor
- Lead sponsor
- Radiation Therapy Oncology GroupResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI); NRG Oncology
- First posted
- Nov 26, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Supportive care
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Amifostine may be an effective treatment for the toxic side effects caused by radiation therapy and chemotherapy. It is not yet known whether chemotherapy and radiation therapy are more effective with or without amifostine for non-small cell lung cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of amifostine in treating patients who have stage II or stage III non-small cell lung cancer that cannot be surgically removed and who are undergoing chemotherapy and radiation therapy.
Conditions
- Drug/Agent Toxicity by Tissue/Organ
- Lung Cancer
- Oral Complications
- Radiation Toxicity
Interventions
filgrastimBiological
amifostine trihydrateDrug
carboplatinDrug
paclitaxelDrug
radiation therapyRadiation
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
264 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham Comprehensive Cancer Center
Birmingham, Alabama
Huntsville Hospital System
Huntsville, Alabama
Comprehensive Cancer Institute of Huntsville
Huntsville, Alabama
MBCCOP - Gulf Coast
Mobile, Alabama
Alabama Oncology, LLC
Montgomery, Alabama
Radiation Oncology Associates of West Alabama
Tuscallosa, Alabama
Providence Alaska Medical Center
Anchorage, Alaska
Foundation for Cancer Research and Education
Phoenix, Arizona
Arizona Cancer Center
Tucson, Arizona
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Mount Diablo Medical Center
Concord, California
Cancer Center and Beckman Research Institute, City of Hope
Duarte, California
California Cancer Center
Fresno, California
Saint Agnes Cancer Center
Fresno, California
Glendale Memorial Hospital and Health Center
Glendale, California
Sutter Health West Cancer Research Group
Greenbrae, California
University of California San Diego Cancer Center
La Jolla, California
Loma Linda University Medical Center
Loma Linda, California
Veterans Affairs Medical Center - Long Beach
Long Beach, California
USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California
CCOP - Bay Area Tumor Institute
Oakland, California
Huntington Cancer Center
Pasadena, California
Cancer Care Center
Pomona, California
Radiation Oncology Center - Sacramento
Sacramento, California
Radiation Medical Group, Inc.
San Diego, California
UCSF Cancer Center and Cancer Research Institute
San Francisco, California
O'Connor Hospital
San Jose, California
CCOP - Santa Rosa Memorial Hospital
Santa Rosa, California
David Grant Medical Center
Travis Air Force Base, California
Memorial Hospital Cancer Center
Colorado Springs, Colorado
University of Colorado Cancer Center
Denver, Colorado
Saint Mary's Hospital and Medical Center
Grand Junction, Colorado
CCOP - Christiana Care Health Services
Wilmington, Delaware
Walter Reed Army Medical Center
Washington D.C., District of Columbia
Lykes Center for Radiation Therapy
Clearwater, Florida
Halifax Medical Center
Daytona Beach, Florida
Radiation Therapy Associates - Fort Myers
Fort Myers, Florida
University of Florida Health Science Center
Gainesville, Florida
Health First Holmes Regional Medical Center
Melbourne, Florida
Showing 40 of 264 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.